34 employees
Prelude delivers actionable tools to manage early stage breast cancer with the DCIS test that enables personalized treatment.
2009
$20M
from 1 investors over 1 rounds
PreludeDx raised $20M on March 22, 2022
Investors: Canepa Healthcare, LLC